Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06021431 · ClinicalTrials.gov registry record · NA

Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT

A NA study of Opioid Use Disorder, sponsored by BehaVR.

Active
Registry status
NA
Development phase
128
Enrollment target
2
Study locations

NCT06021431: Active NA study of Opioid Use Disorder, sponsored by BehaVR.

NCT06021431 is a NA study of Opioid Use Disorder that is active but no longer recruiting, run by BehaVR. The registered enrollment target is 128 participants, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (97% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06021431, a NA study of Opioid Use Disorder, is active but no longer recruiting, sponsored by BehaVR.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
128 participants
Enrollment target
2
Study locations

Study Summary

The goal of this clinical trial is to examine the usefulness of a virtual reality-delivered intervention for individuals with opioid use disorder who are taking medication. The main question it aims to answer is will people with opioid use disorder who receive the study intervention, Mindfulness-Oriented Recovery Enhancement in Virtual Reality (MORE-VR), have fewer days in which they use opioids than will people who just receive their usual treatment. Participants will be randomly assigned to either receive 8 weekly sessions of MORE-VR in addition to their usual treatment, or treatment as usual only. Researchers will compare these groups at the end of treatment and three months after treatment is over on number of days of opioid use and time until first opioid use lapse, as well as drug craving and mood.

Primary Outcome

Days of opioid use assessed with the Timeline Followback method, ecological momentary assessments, and/or drug toxicology screen

Conditions Studied

Interventions

  • OTHER Treatment as Usual
  • DEVICE MORE-VR

Study Locations (2)

California

  • University of California, San Diego - La Jolla

Utah

  • University of Utah - Salt Lake City

Trial Details

FieldValue
Enrollment Target 128 participants
Start Date 2023-09-07
Est. Completion 2025-09
Phase NA
BehaVR

1 total trials

What the registry record for NCT06021431 still lists

NCT06021431 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 4,656-participant average among 257 other Opioid Use Disorder trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Opioid Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Treatment as Usual is the first listed.

NCT06021431 reports a single indexed study location in California, Utah.

Frequently Asked Questions

What is clinical trial NCT06021431 about?

NCT06021431 is a clinical study titled "Virtual Reality Cognitive-Affective Training for Opioid Use Disorder- A Phase 2 RCT". The goal of this clinical trial is to examine the usefulness of a virtual reality-delivered intervention for individuals with opioid use disorder who are taking medication. The main question it aims to answer is will people with opioid use disorder who receive the study intervention, Mindfulness-Ori...

What is the current status of trial NCT06021431?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 128 participants. The study started on 2023-09-07. Estimated completion is 2025-09.

What conditions does trial NCT06021431 study?

This clinical trial studies the following conditions: Opioid Use Disorder.

What interventions are being tested in trial NCT06021431?

The interventions under investigation include: Treatment as Usual (OTHER), MORE-VR (DEVICE).

Who is sponsoring clinical trial NCT06021431?

This trial is sponsored by BehaVR, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06021431 being conducted?

This trial has 2 study locations across California, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Opioid Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06021431's enrollment target sits among peer trials

128 117th of 257 higher than 140 of 257 other Opioid Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Opioid Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02870738 · 128 participants · Phase 2

    Bladder Directed vs. Pelvic Floor Therapy in IC/BPS

  • NCT03294460 · 128 participants · Phase 1

    Nicotinic Receptor Genetic Variation and Alcohol Reward

  • NCT04149977 · 128 participants · NA

    Blood Flow Restriction Therapy in Lower Limb Extensor Injuries

  • NCT04373057 · 128 participants · Phase 1

    Prebiotic Galacto-oligosaccharide and Acute GVHD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06021431, the US trial registry maintained by the National Library of Medicine. NCT06021431 (mid enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.